Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer-Reference-Cited by-同舟云学术

Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer

Published:2022-01-02 Issue:1 Volume:7 Page:131-149
ISSN:2380-8993
Container-title:Expert Review of Precision Medicine and Drug Development
language:en
Short-container-title:Expert Review of Precision Medicine and Drug Development

Author:

Rosellini Matteo¹,Marchetti Andrea¹,Tassinari Elisa¹,Nuvola Giacomo¹,Rizzo Alessandro²,Santoni Matteo³,Mollica Veronica¹⁴,Massari Francesco¹⁴

Affiliation:

1. Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

2. Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico “Don Tonino Bello,”, I.R.C.C.S. Istituto Tumori “Giovanni Paolo II,”, Bari, Italy

3. Oncology Unit, Macerata Hospital, Via Santa Lucia 2, Macerata, Italy

4. Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi University Hospital, University of Bologna, Bologna, Italy

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/23808993.2022.2156786

Reference160 articles.

1. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

2. Systemic Therapy for Metastatic Renal-Cell Carcinoma

3. Renal-Cell Carcinoma

4. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

5. Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study;European Urology Oncology;2024-04

2. Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma;Expert Review of Precision Medicine and Drug Development;2024-03-18

3. Diagnostic liquid biopsy biomarkers in renal cell cancer;Nature Reviews Urology;2023-09-27

4. Diagnostic liquid biopsy biomarkers in renal cell cancer;NAT REV UROL;2023

5. An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma;Expert Opinion on Drug Safety;2023-04-03